| Literature DB >> 35237234 |
Mengdi Liu1,2, Xusheng Zhao1,3, Yuanyuan Peng1, Jiahua Zheng1, Kaixuan Guo1, Yanli Fan1, Lei Jiang1, Aimin Yang1, Na Cui1, Guimin Hao1, Wei Wang1.
Abstract
OBJECTIVES: Previous studies showed that age is the most important factor that determines the outcome after embryo transfer (ET), with either in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), regardless whether fresh or frozen cycles. The average cumulative live birth rate (CLBR) following a single ovarian stimulation cycle in women of advanced reproductive age (≥38 years of age) has been reported to be 22.6-34.1%. The purpose of this study is to compare the CLBR after a single ovarian stimulation cycle in women of different advanced reproductive age bracket (38/39, 40/41, 42/43 years of age or older), and to explore the factors (e.g., age, type of infertility, body mass index (BMI), ovarian stimulation protocols) associated with CLBR.Entities:
Keywords: advanced reproductive age; assisted reproductive technology; in vitro fertilization; intracytoplasmic sperm injection; live birth
Mesh:
Substances:
Year: 2022 PMID: 35237234 PMCID: PMC8882593 DOI: 10.3389/fendo.2022.792159
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Figure 1Study flow chart.
Ovarian stimulation protocols in different age brackets and data of in vitro fertilization and embryo transfer.
| Total | 38/39 y | 40/41 y | 42/43 y | ≥44 y |
| |
|---|---|---|---|---|---|---|
| N = 826 | N = 424 | N = 226 | N = 118 | N = 58 | ||
| GnRH antagonist | 37.41% (309/826) | 31.83% (135/424) | 35.84% (81/226) | 47.46% (56/118) | 63.79% (37/58) | <0.001 |
| GnRH-a long | 26.63% (220/826) | 33.49% (142/424) | 20.80% (47/226) | 22.03% (26/118) | 8.62% (5/58) | <0.001 |
| Micro-stimulation | 21.31% (176/826) | 18.16% (77/424) | 25.66% (58/226) | 23.73% (28/118) | 22.41% (13/58) | 1.38 |
| GnRH-a ultra-long | 12.35% (102/826) | 15.09% (64/424) | 14.16% (32/226) | 4.24% (5/118) | 1.72% (1/58) | <0.001 |
| Progestin primed ovarian stimulation | 2.30% (19/826) | 1.42% (6/424) | 3.54% (8/226) | 2.54% (3/118) | 3.44% (2/58) | 0.335 |
| Number of oocytes | 6 (3,10) | 7 (4,10) | 6 (4,10) | 5 (3,8) | 3 (2,5.25) | <0.001 |
| Number of transferable embryos | ||||||
| 1 | 130 | 12.50% (53/424) | 15.93% (36/226) | 22.88% (27/118) | 24.14% (14/58) | 0.012 |
| 2 | 342 | 46.46% (197/424) | 34.51% (78/226) | 36.44% (43/118) | 41.37% (24/58) | 0.018 |
| 3 | 160 | 13.21% (56/424) | 27.43% (62/226) | 23.73% (28/118) | 24.14% (14/58) | <0.001 |
| 4–11 | 194 | 27.83% (118/424) | 22.12% (50/226) | 16.95% (20/118) | 10.34% (6/58) | 0.004 |
| Number of transplant cycles | ||||||
| 1 | 678 | 77.12% (327/424) | 86.28% (195/226) | 87.29% (103/118) | 91.38% (53/58) | 0.002 |
| 2 | 129 | 20.75% (88/424) | 10.62% (24/226) | 10.17% (12/118) | 8.62% (5/58) | 0.001 |
| ≥3 | 19 | 2.12% (9/424) | 3.10% (7/226) | 2.54% (3/118) | 0.0% (0/58) | 0.553 |
Cumulative live birth after a single ovarian stimulation cycle and pregnancy outcomes in first ET cycles.
| Total | 38/39 y | 40/41 y | 42/43 y | ≥44 y |
| |
|---|---|---|---|---|---|---|
| N = 826 | N = 424 | N = 226 | N = 118 | N = 58 | ||
| Cumulative live birth | 26.27% (217/826) | 32.31% (137/424) | 26.99% (61/226) | 14.40% (17/118) | 3.44% (2/58) | <0.001 |
| Fresh ET cycle | 66.95% (553/826) | 62.03% (263/424) | 67.70% (153/226) | 77.97% (92/118) | 77.58% (45/58) | 0.003 |
| Clinical pregnancy rate (%) | 26.15% (216/826) | 29.48% (125/424) | 29.20% (66/226) | 17.80% (21/118) | 6.89% (4/58) | <0.001 |
| Live birth rate(%) | 21.43% (177/826) | 25.94% (110/424) | 22.57% (51/226) | 11.86% (14/118) | 3.44% (2/58) | <0.001 |
| Abortion rate(%) | 24.54% (53/216) | 17.60% (22/125) | 31.82% (21/66) | 38.10% (8/21) | 50.00% (2/4) | 0.035 |
| Multiple pregnancy rate (%) | 13.43% (29/216) | 16.80% (21/125) | 9.09% (6/66) | 9.52% (2/21) | 25.00% (1/4) | 0.407 |
Cumulative live birth of different ovarian stimulation protocols in different age brackets.-, not analyzed since the number of the subjects is <15.
| Total | 38/39y | 40/41y | 42/43y | ≥44y | |
|---|---|---|---|---|---|
| N=424 | N=226 | N=118 | N=58 | ||
| GnRH antagonist | 22.0% | 27.4% | 29.6% | 10.7% | 2.7% |
| (68/309) | (37/135) | (24/81) | (6/56) | (1/37) | |
| GnRH-a long | 33.2% | 38.7% | 23.4% | 23.1% | – |
| (73/220) | (55/142) | (11/47) | (6/26) | (1/5) | |
| Micro-stimulation | 20.5% | 22.1% | 24.1% | 17.9% | – |
| (36/176) | (17/77) | (14/58) | (5/28) | (0/13) | |
| GnRH-a ultra-long | 38.2% | 42.2% | 37.5% | – | – |
| (39/102) | (27/64) | (12/32) | (0/5) | (0/1) | |
| Progestin primed ovarian stimulation | 10.5% | – | – | – | – |
| (2/19) | (1/6) | (1/8) | (0/3) | (0/2) | |
|
| <0.001 | 0.014 | 0.482 | 0.307 | – |
Baseline characteristics in different age brackets.
| Total | 38/39 y | 40/41 y | 42/43 y | ≥44 y |
| |
|---|---|---|---|---|---|---|
| N = 826 | N = 424 | N = 226 | N = 118 | N = 58 | ||
| BMI (kg/m2) | 23.44 (21.83, 25.90) | 23.34 (21.60, 25.70) | 23.90 (22.12, 25.99) | 23.42 (21.86, 26.04) | 24.61 (22.00, 26.73) | 0.061 |
| Primary infertility, | 180 (21.79%) | 103 (24.29%) | 46 (20.35%) | 22 (18.64%) | 9 (15.51%) | 0.277 |
| Years of infertility | 4 (2,8) | 4 (2,8) | 4 (2,8) | 2.5 (1,6.75) | 2 (1,9) | 0.229 |
| AFC | 8 (6,11) | 9 (6,12) | 8 (6,11) | 6 (4.5,10) | 5 (4,7) | <0.001 |
| FSH (mIU/ml) | 7.78 (6.49,10.00) | 7.62 (6.37,9.74) | 7.76 (6.44,9.67) | 8.42 (6.82,10.85) | 8.95 (7.22,11.30) | 0.008 |
| LH (mIU/ml) | 3.93 (2.94,5.40) | 3.93 (2.92,5.54) | 4.11 (2.95,5.26) | 3.82 (2.95,5.36) | 3.9 (3.00,8.64) | 0.989 |
| E2 (ng/L) | 39.00 (27.00, 59.00) | 39.00 (26.50, 55.00) | 42.00 (28.00, 61.00) | 37.00 (25.00, 59.00) | 44.00 (26.50, 69.00) | 0.401 |
| AMH (ng/ml) | 1.49 (0.90,2.57) | 1.74 (1.09,2.71) | 1.64 (1.06,2.57) | 1.10 (0.52,2.67) | 0.83 (0.48,1.25) | 0.231 |
| Endometrium thickness (mm) | 10 (9,11) | 10 (9,11) | 10 (9,12) | 10 (8.1,11) | 10 (9,11) | 0.832 |